Pharmacogenomics and therapy in arrhythmic disease

Abstract

Abstract: Therapeutic dose and toxic dose about antiarrhythmic drugs are extremely near, and the individual difference is easy to induce drug adverse reaction. Studies on pharmacogenomics of antiarrhythmic drugs have correctly conducted the use of drugs in order to achieve desirable treatment and effectiveness and reduce side effects. This article presents an overview of the current research progress of pharmacogenomics of antiarrhythmic drugs.

Key words: Pharmacogenomics, Antiarrhythmic drugs, Genomic polymorphism, Drug metabolizing enzyme

CLC Number:

R969

SHEN Ying, DENG Jie, SONG Hong-tao. Pharmacogenomics and therapy in arrhythmic disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1315-1320.

References

[1] Ovaska H,Ludman A,Spencer EP,et al.Propafenone poisoning-a case report with plasma propafenone concentrations[J]. J Med Toxicol, 2010, 6(1):37-40.
[2] Magnus IS, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116(3): 496-526.
[3] Taguchi M, Nozawa T, Kameyama T, et al. Effect of CYP2D6^*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients[J]. Eur J Clin Pharmacol, 2003, 59(5/6): 385-388.
[4] Sharp CF, Gardiner SJ, Jensen BP, et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure CYP2D6, metoprolol and heart failure[J]. Pharmacogenomics J, 2009, 9(3): 175-184.
[5] Chen B, Cai WM. Influence of CYP2D6^*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects[J]. Acta Pharmacol Sin, 2003, 24(12): 1277-1280.
[6] 李拴美, 刘端, 朱娟莉, 等. 体外研究人细胞色素P450 3A4等位基因多态性对药物代谢和药物相互作用的影响[J]. 中国医药生物技术, 2009, 4(3): 177-183.
[7] Sheffield LJ, Phillimore HE. CYP3A4 is the most abundant enzyme and is associated with metabolism of about 50% of drugs in clinical use[J]. Clin Biochem Rev, 2009, 30(2): 55-65.
[8] Cheng JWM, Frishman WH, Aronow WS. Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions[J]. Am J Ther, 2009, 16(2): 155-163.
[9] Xu P, Jiang ZP, Zhang BK, et al. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers[J]. Pharmacology, 2008, 82(3): 221-227.
[10] McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG[J].Pharmacogenomics J, 2009, 9(3): 194-201.
[11] Ni LN, Li JY, Miao KR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia[J]. Med Oncol,2010 Mar 4. [Epub ahead of print].
[12] Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1(SLC22A1) affecting transport functions[J]. Biochem Biophys Res Comman, 2004, 313(3): 789-793.
[13] Zill P, Baghai TC, Engel R, et al. Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response[J]. Am J Med Genet B Neuropsychiatr Genet, 2003, l20(1): 85-89.
[14] Xie HC, Dishy V, Sofowora G, et al. Arg389Gly betal-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo[J]. Pharmacogenetics, 2001, 11(3): 191-197.
[15] Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol[J]. Clin Pharmacol Ther, 2003, 74(1): 44-52.
[16] Liu J, Liu ZQ, Tan ZR, et al. Arg389Gly polymorphism of betaladrenergic receptor is associated with the cardiovacular response to metoprolol[J]. Clin Pharmacol Ther, 2003, 74(4): 372-379.
[17] 李为民, 甘润韬. β₁肾上腺素受体基因多态性与心血管疾病的研究进展[J]. 心肺血管病杂志, 2007, 26(3):185-187.
[18] Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure[J]. Cardiovasc Drugs Ther, 2010, 24(1): 49-60.
[19] Allen N, Chen C, Agrawal R, et al. β₁ and β₂ Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents [J]. J Crit Care, 2007, 26(1): 2-9.
[20] Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome[J]. JAMA, 2005, 294(12): 1526-1533.
[21] Lizotte E, Junttila MJ, Dube MP, et al. Genetic Modulation of Brugada Syndrome by a Common Polymorphism[J]. J Cardiovasc Electrophysiol, 2009, 20(10): 1137-1141.
[22] 李绪勇, 李晓艳, 蒋学俊, 等. 普罗帕酮对HERG钾通道孔胞膜外侧氨基酸突变前后的作用[J]. 心血管康复医学杂志, 2010, 19(1): 49-53.
[23] Gaikovitch EA, Cascorbi I, Mrozikiewiez PM, el a1. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population[J]. Eur J Clin Pharmacol, 2003, 59(4): 303-331.